What Is MEDVi MEDVi is a telehealth platform focused on compounded semaglutide and tirzepatide
Research indicates higher doses of semaglutide produce more potent effects on satiety and other factors that contribute to weight loss
This may include a prescription for semaglutide in an injectable or oral formulation, when clinically appropriate, alongside recommendations for diet, exercise, and lifestyle changes to support overall wellness
In clinical trials, many people reached about 5% weight loss around 12 to 16 weeks of treatment , often just as they were approaching higher doses
Semaglutide 7 mg was superior to sitagliptin as well
Using without a prescription, purchasing without research, and careless administration make compounded semaglutide unsafe